Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Irritable Bowel Syndrome

Free Subscription Articles published in Aliment Pharmacol Ther Retrieve available abstracts of 108 articles: HTML format

Single Articles

July 2026
1. JAVED A
   Letter: SCFA Enrichment in IBS-D-A Disease Subtype or a Transit-Driven Phenomenon?
   Aliment Pharmacol Ther. 2026 Jul 27. doi: 10.1111/apt.70891.
   PubMed    
   
   
   
2. CRISTOFORI F, Dargenio VN, Castellaneta SP, Francavilla R, et al
   Letter: Low FODMAP Therapy in Paediatric Irritable Bowel Syndrome: Balancing Efficacy, Expectancy and Safety. Authors' Reply.
   Aliment Pharmacol Ther. 2026 Jul 20. doi: 10.1111/apt.70866.
   PubMed    
   
   
   June 2026
3. HAKIMI Y, Giles E
   Letter: Low FODMAP Therapy in Paediatric Irritable Bowel Syndrome: Balancing Efficacy, Expectancy and Safety.
   Aliment Pharmacol Ther. 2026 Jun 29. doi: 10.1111/apt.70830.
   PubMed    
   
   
   
4. GARCIA-CEDILLO MF, la Torre MFH, Arenas-Martinez JS, Coss-Adame E, et al
   Letter: Low-FODMAP Diet in Irritable Bowel Syndrome-Beyond the Hype! Authors' Reply.
   Aliment Pharmacol Ther. 2026 Jun 19. doi: 10.1111/apt.70812.
   PubMed    
   
   
   
5. SHIHA MG, Keszthelyi D
   Letter: Low-FODMAP Diet in Irritable Bowel Syndrome-Beyond the Hype!
   Aliment Pharmacol Ther. 2026 Jun 12. doi: 10.1111/apt.70792.
   PubMed    
   
   
   
6. 
   Correction to 'Effects of a Personalised FODMAP Diet Versus the National Institute for Health and Care Excellence (NICE) Dietary Advice on Symptom Control in Patients With Irritable Bowel Syndrome: Randomised Clinical Trial'.
   Aliment Pharmacol Ther. 2026 Jun 11. doi: 10.1111/apt.70788.
   PubMed    
   
   
   May 2026
7. VELDMAN F, Innocenti F, Aziz I, Fikree A, et al
   Prevalence and Burden of Fatigue Across Disorders of Gut-Brain Interaction: Results From the Rome Foundation Global Epidemiology Study.
   Aliment Pharmacol Ther. 2026 May 28. doi: 10.1111/apt.70756.
   PubMed     Abstract available
   
   
   
8. CRISTOFORI F, Celano G, Dargenio VN, Apa CA, et al
   Clinical trial: Efficacy of a Low FODMAP Diet in Paediatric Irritable Bowel Syndrome-A Randomised Crossover Trial With Exploratory Metabolomic Analysis.
   Aliment Pharmacol Ther. 2026 May 13. doi: 10.1111/apt.70718.
   PubMed     Abstract available
   
   
   April 2026
9. CONLEY TE, Duncan A, Modasia A, Ford AC, et al
   The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical Relevance.
   Aliment Pharmacol Ther. 2026 Apr 17. doi: 10.1111/apt.70677.
   PubMed     Abstract available
   
   
   
10. ELDESOUKI MH, Gayam S
    Editorial: New Insights Into the Aetiopathogenesis of Post-Infective Irritable Bowel Syndrome and Functional Dyspepsia: A Significant Step Forward but What Next? Authors' Reply.
    Aliment Pharmacol Ther. 2026 Apr 15. doi: 10.1111/apt.70676.
    PubMed    
    
    
    March 2026
11. WHELAN K
    Editorial: Personalising the Low FODMAP Diet to Achieve Therapeutic Benefit Whilst Reducing Burden and Maintaining Dietary Diversity in Irritable Bowel Syndrome.
    Aliment Pharmacol Ther. 2026 Mar 25. doi: 10.1111/apt.70626.
    PubMed    
    
    
    
12. COSS-ADAME E, Garcia-Cedillo MF, Huerta-de la Torre MF, Arenas-Martinez JS, et al
    Editorial: Personalising the Low FODMAP Diet to Achieve Therapeutic Benefit Whilst Reducing Burden and Maintaining Dietary Diversity in Irritable Bowel Syndrome. Authors' Reply.
    Aliment Pharmacol Ther. 2026 Mar 25. doi: 10.1111/apt.70631.
    PubMed    
    
    
    
13. SASEGBON A, Vasant DH
    Editorial: New Insights Into the Aetiopathogenesis of Post-Infective Irritable Bowel Syndrome and Functional Dyspepsia: A Significant Step Forward but What Next?
    Aliment Pharmacol Ther. 2026 Mar 17. doi: 10.1111/apt.70627.
    PubMed    
    
    
    
14. ELDESOUKI MH, Kloub M, Elfert K, Ibrahim A, et al
    Cohort Study: Long-Term Risk and Healthcare Burden of Irritable Bowel Syndrome Following Infection Enteritis in 202,244 Patients.
    Aliment Pharmacol Ther. 2026 Mar 13. doi: 10.1111/apt.70602.
    PubMed     Abstract available
    
    
    
15. GARCIA-CEDILLO MF, Huerta-de la Torre MF, Arenas-Martinez JS, Coss-Adame E, et al
    Effects of a Personalised FODMAP Diet Versus the National Institute for Health and Care Excellence (NICE) Dietary Advice on Symptom Control in Patients With Irritable Bowel Syndrome: Randomised Clinical Trial.
    Aliment Pharmacol Ther. 2026 Mar 5. doi: 10.1111/apt.70601.
    PubMed     Abstract available
    
    
    February 2026
16. GOODOORY VC, Khasawneh M, Riggott C, Vasant DH, et al
    Novel Symptom Subgroups in Patients With Irritable Bowel Syndrome Are Associated With Healthcare Utilisation in Secondary and Tertiary Care.
    Aliment Pharmacol Ther. 2026 Feb 19. doi: 10.1111/apt.70583.
    PubMed     Abstract available
    
    
    January 2026
17. ZHENG NS, Bar N, Kuo B, Staller K, et al
    Research Communication: Healthcare Utilisation Patterns in Patients With Irritable Bowel Syndrome Across an Integrated Healthcare System.
    Aliment Pharmacol Ther. 2026;63:294-298.
    PubMed     Abstract available
    
    
    December 2025
18. KHASAWNEH M, Goodoory VC, Ng CE, Ford AC, et al
    Stability of Classification Systems for Irritable Bowel Syndrome.
    Aliment Pharmacol Ther. 2025 Dec 25. doi: 10.1111/apt.70503.
    PubMed     Abstract available
    
    
    
19. ALSAKARNEH S, Al Ta'ani O, Mahmoud MY, Syn WK, et al
    Comprehensive Risk Profile of Gastrointestinal and Extra Articular Comorbidities in Ehlers-Danlos Syndrome: A Propensity-Matched Analysis of 118,256 Individuals.
    Aliment Pharmacol Ther. 2025 Dec 23. doi: 10.1111/apt.70506.
    PubMed     Abstract available
    
    
    November 2025
20. CHUAH KH, Loo QY, Loh AJC, Leong JY, et al
    Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome-It Is Nice to Have a Choice. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Nov 24. doi: 10.1111/apt.70469.
    PubMed    
    
    
    
21. HALMOS EP, Gibson PR
    Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome-It Is Nice to Have a Choice.
    Aliment Pharmacol Ther. 2025 Nov 24. doi: 10.1111/apt.70452.
    PubMed    
    
    
    
22. SHIN A, Xu H, Sarnoff R, Church A, et al
    Research Communication: An Observational Cohort Study on Risk of Ovarian Cancer in Women with Irritable Bowel Syndrome.
    Aliment Pharmacol Ther. 2025;62:944-947.
    PubMed     Abstract available
    
    
    October 2025
23. CHUAH KH, Loo QY, Loh AJC, Leong JY, et al
    Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome.
    Aliment Pharmacol Ther. 2025 Oct 16. doi: 10.1111/apt.70420.
    PubMed     Abstract available
    
    
    
24. DILMAGHANI S, BouSaba J, Lupianez-Merly C, Prokop L, et al
    Meta-Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea.
    Aliment Pharmacol Ther. 2025 Oct 15. doi: 10.1111/apt.70390.
    PubMed     Abstract available
    
    
    
25. BUTT MF, Goodoory VC, Ng CE, Black CJ, et al
    Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom.
    Aliment Pharmacol Ther. 2025 Oct 8. doi: 10.1111/apt.70400.
    PubMed     Abstract available
    
    
    July 2025
26. BAILLIE S, Saxena S, Jayasooriya N, Bottle A, et al
    Pain and Sedative Medication Use Among Individuals With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study.
    Aliment Pharmacol Ther. 2025 Jul 2. doi: 10.1111/apt.70247.
    PubMed     Abstract available
    
    
    April 2025
27. KHUNSRIRAKSAKUL C, Ziegler O, Liu D, Kulaylat AS, et al
    The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population-Based Study.
    Aliment Pharmacol Ther. 2025 Apr 11. doi: 10.1111/apt.70147.
    PubMed     Abstract available
    
    
    February 2025
28. CAMILLERI M, Ford AC
    Review Article: Surrogate Endpoints to Assess Treatment Efficacy in Disorders of Gut-Brain Interaction of Lower Gastrointestinal Tract.
    Aliment Pharmacol Ther. 2025 Feb 2. doi: 10.1111/apt.18527.
    PubMed     Abstract available
    
    
    January 2025
29. SHIN A
    Editorial: Alpha(2)-Delta Ligands in Irritable Bowel Syndrome.
    Aliment Pharmacol Ther. 2025 Jan 30. doi: 10.1111/apt.18528.
    PubMed    
    
    
    
30. HOUGHTON LA, Gao S, Gilbert SA, Coffin B, et al
    Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha-2-Delta Ligand PD-217,014 in Patients With Irritable Bowel Syndrome.
    Aliment Pharmacol Ther. 2025 Jan 15. doi: 10.1111/apt.18487.
    PubMed     Abstract available
    
    
    November 2024
31. BUTT MF, Corsetti M
    Editorial: Rebuilding Rome-Revising Diagnostic Criteria for Irritable Bowel Syndrome.
    Aliment Pharmacol Ther. 2024 Nov 14. doi: 10.1111/apt.18400.
    PubMed    
    
    
    October 2024
32. GOODOORY VC, Riggott C, Khasawneh M, Black CJ, et al
    Validating Simple Modifications to the Rome IV Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care.
    Aliment Pharmacol Ther. 2024 Oct 28. doi: 10.1111/apt.18363.
    PubMed     Abstract available
    
    
    
33. O'CONNOR A, Gill S, Neary E, White S, et al
    Impact of HADS Anxiety and Depression Scores on the Efficacy of Dietary Interventions for Irritable Bowel Syndrome.
    Aliment Pharmacol Ther. 2024 Oct 11. doi: 10.1111/apt.18337.
    PubMed     Abstract available
    
    
    
34. RIGGOTT C, Ford AC, Gracie DJ
    Review article: The role of the gut-brain axis in inflammatory bowel disease and its therapeutic implications.
    Aliment Pharmacol Ther. 2024 Oct 5. doi: 10.1111/apt.18192.
    PubMed     Abstract available
    
    
    August 2024
35. SHIN A
    Editorial: Disordered eating and irritable bowel syndrome-Do maladaptive eating and weight control behaviours increase risk of a maladaptive gut?
    Aliment Pharmacol Ther. 2024 Aug 28. doi: 10.1111/apt.18232.
    PubMed    
    
    
    
36. YANG K, Kwon S, Burton-Murray H, Kuo B, et al
    Maladaptive weight control and eating behaviours in female adolescents/young adults are associated with increased risk of irritable bowel syndrome in adulthood: Results from the Growing Up Today Study (GUTS).
    Aliment Pharmacol Ther. 2024 Aug 5. doi: 10.1111/apt.18197.
    PubMed     Abstract available
    
    
    
37. LUPIANEZ-MERLY C, Jencks K, Dilmaghani S, Ferber M, et al
    Letter (brief communication): A pilot study of hemp hull bio gut fibre (BGF) to reduce intestinal permeability in IBS-BAD.
    Aliment Pharmacol Ther. 2024;60:544-545.
    PubMed    
    
    
    June 2024
38. WAIDYARATNE G, Daboul J, Liyanarachchi S, Chakraborty S, et al
    The evaluation and analysis of irritable bowel syndrome-related short videos on social media (TikTok).
    Aliment Pharmacol Ther. 2024 Jun 10. doi: 10.1111/apt.18096.
    PubMed     Abstract available
    
    
    
39. SPERBER AD, Freud T, Palsson OS, Bangdiwala SI, et al
    The aging gastrointestinal tract: Epidemiology and clinical significance of disorders of gut-brain interaction in the older general population.
    Aliment Pharmacol Ther. 2024 Jun 4. doi: 10.1111/apt.18103.
    PubMed     Abstract available
    
    
    April 2024
40. ALIU A, Bosch DHCA, Keszthelyi D, Rezazadeh Ardabili A, et al
    Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission.
    Aliment Pharmacol Ther. 2024 Apr 8. doi: 10.1111/apt.17988.
    PubMed     Abstract available
    
    
    February 2024
41. STALLER K, Ludvigsson JF
    Letter: Irritable bowel syndrome and antibiotics-Authors' reply.
    Aliment Pharmacol Ther. 2024;59:422.
    PubMed    
    
    
    
42. LONGSTRETH GF
    Letter: Irritable bowel syndrome and antibiotics.
    Aliment Pharmacol Ther. 2024;59:421.
    PubMed    
    
    
    
43. BLACK CJ, Gracie DJ
    Editorial: A Mediterranean diet for IBS-Is healthy and inclusive eating the way forward?
    Aliment Pharmacol Ther. 2024;59:571-572.
    PubMed    
    
    
    January 2024
44. SHIN A
    Editorial: Antibiotics as a risk factor for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2024;59:130-131.
    PubMed    
    
    
    
45. CHANG HC, Gau SY
    Letter: antibiotics prescription and new-onset irritable bowel syndrome.
    Aliment Pharmacol Ther. 2024;59:299.
    PubMed    
    
    
    December 2023
46. STALLER K, Ludvigsson JF
    Letter: Antibiotics prescription and new-onset irritable bowel syndrome-Authors' reply.
    Aliment Pharmacol Ther. 2023 Dec 8. doi: 10.1111/apt.17827.
    PubMed    
    
    
    November 2023
47. STAUDACHER HM, Mahoney S, Canale K, Opie RS, et al
    Clinical trial: A Mediterranean diet is feasible and improves gastrointestinal and psychological symptoms in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023 Nov 15. doi: 10.1111/apt.17791.
    PubMed     Abstract available
    
    
    
48. DEVENNEY J, Hasan SS, Morris J, Whorwell PJ, et al
    Clinical trial: predictive factors for response to gut-directed hypnotherapy for refractory irritable bowel syndrome, a post hoc analysis.
    Aliment Pharmacol Ther. 2023 Nov 5. doi: 10.1111/apt.17790.
    PubMed     Abstract available
    
    
    
49. EL-SALHY M, Gilja OH, Hatlebakk JG
    Letter: A step forward towards a standard FMT protocol for IBS.
    Aliment Pharmacol Ther. 2023;58:1115-1116.
    PubMed    
    
    
    
50. LESMANA E, Grover M
    Editorial: Faecal microbiota transplantation in IBS-Moving closer or away from success?
    Aliment Pharmacol Ther. 2023;58:950-951.
    PubMed    
    
    
    
51. SU Q, Yau YK, Ng SC
    Editorial: Faecal microbiota transplantation in IBS-Moving closer or away from success? Authors' reply.
    Aliment Pharmacol Ther. 2023;58:952-953.
    PubMed    
    
    
    October 2023
52. DAJTI E, Frazzoni L, Iascone V, Secco M, et al
    Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
    Aliment Pharmacol Ther. 2023 Oct 12. doi: 10.1111/apt.17754.
    PubMed     Abstract available
    
    
    September 2023
53. STALLER K, Olen O, Soderling J, Roelstraete B, et al
    Antibiotic use as a risk factor for irritable bowel syndrome: Results from a nationwide, case-control study.
    Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17736.
    PubMed     Abstract available
    
    
    
54. YAU YK, Su Q, Xu Z, Tang W, et al
    Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea.
    Aliment Pharmacol Ther. 2023 Sep 5. doi: 10.1111/apt.17703.
    PubMed     Abstract available
    
    
    
55. MELTON SL, Halmos EP
    Editorial: One step closer to personalised nutrition therapy for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023;58:554-555.
    PubMed    
    
    
    August 2023
56. CHUAH KH, Black CJ, Tee V, Lim SZ, et al
    Editorial: Recognising the regional variations in profile of irritable bowel syndrome-better late than never! Authors' reply.
    Aliment Pharmacol Ther. 2023;58:476-477.
    PubMed    
    
    
    
57. GHOSHAL UC
    Editorial: Recognising the regional variations in profile of irritable bowel syndrome-better late than never!
    Aliment Pharmacol Ther. 2023;58:474-475.
    PubMed    
    
    
    July 2023
58. LUO Y, Jodorkovsky D, Singh P, Keefer LA, et al
    Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023;58:137-138.
    PubMed    
    
    
    
59. DAI C, Huang YH, Jiang M
    Letter: Post-COVID-19 functional dyspepsia and irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023;58:126-127.
    PubMed    
    
    
    
60. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome-authors' reply.
    Aliment Pharmacol Ther. 2023;58:139-140.
    PubMed    
    
    
    
61. MARASCO G, Maida M, Cremon C, Barbaro MR, et al
    Letter: Post-COVID-19 functional dyspepsia and irritable bowel syndrome-Authors' reply.
    Aliment Pharmacol Ther. 2023;58:128-129.
    PubMed    
    
    
    June 2023
62. SO D, Yao CK, Gill PA, Thwaites PA, et al
    Detection of changes in regional colonic fermentation in response to supplementing a low FODMAP diet with dietary fibres by hydrogen concentrations, but not by luminal pH.
    Aliment Pharmacol Ther. 2023 Jun 30. doi: 10.1111/apt.17629.
    PubMed     Abstract available
    
    
    
63. WILSON B, Kanno T, Slater R, Rossi M, et al
    Faecal and urine metabolites, but not gut microbiota, may predict response to low FODMAP diet in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023 Jun 14. doi: 10.1111/apt.17609.
    PubMed     Abstract available
    
    
    
64. GUNN D, Ford A, Farrin A, Spiller R, et al
    Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms-authors' reply.
    Aliment Pharmacol Ther. 2023;57:1337-1338.
    PubMed    
    
    
    
65. SHAH ED
    Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms.
    Aliment Pharmacol Ther. 2023;57:1335-1336.
    PubMed    
    
    
    
66. CHUAH KH, Black CJ, Tee V, Lim SZ, et al
    A prospective comparison of UK and Malaysian patients with irritable bowel syndrome in secondary care.
    Aliment Pharmacol Ther. 2023 Jun 1. doi: 10.1111/apt.17567.
    PubMed     Abstract available
    
    
    May 2023
67. GOODOORY VC, Guthrie EA, Ng CE, Black CJ, et al
    Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1190-1191.
    PubMed    
    
    
    
68. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options! Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1176-1177.
    PubMed    
    
    
    
69. SHARMA A, Rao S
    Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options!
    Aliment Pharmacol Ther. 2023;57:1174-1175.
    PubMed    
    
    
    
70. CHUAH KH, Mahadeva S
    Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients?
    Aliment Pharmacol Ther. 2023;57:1188-1189.
    PubMed    
    
    
    April 2023
71. MARASCO G, Maida M, Cremon C, Barbaro MR, et al
    Meta-analysis: Post-COVID-19 functional dyspepsia and irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023 Apr 10. doi: 10.1111/apt.17513.
    PubMed     Abstract available
    
    
    March 2023
72. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023 Mar 13. doi: 10.1111/apt.17465.
    PubMed     Abstract available
    
    
    
73. GUNN D, Topan R, Barnard L, Fried R, et al
    Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial.
    Aliment Pharmacol Ther. 2023 Mar 3. doi: 10.1111/apt.17426.
    PubMed     Abstract available
    
    
    
74. THWAITES PA, Burgell RE
    Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here?
    Aliment Pharmacol Ther. 2023;57:723-724.
    PubMed    
    
    
    
75. GOODOORY VC, Guthrie EA, Ng CE, Black CJ, et al
    Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:725-726.
    PubMed    
    
    
    February 2023
76. MANTEGAZZA G, Gargari G, Guglielmetti S
    Editorial: bacterial gut symbionts as live biotherapeutic agents in irritable bowel syndrome-a rosy future despite potential long-term safety concerns.
    Aliment Pharmacol Ther. 2023;57:345-346.
    PubMed    
    
    
    
77. QUIGLEY EMM, Stevenson A, Jeffery I, Masters J, et al
    Editorial: bacterial gut symbionts as live biotherapeutic agents in IBS-a rosy future despite potential long-term safety concerns. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:347-348.
    PubMed    
    
    
    
78. WANG L, Alexander JA
    Letter: diet-responsive or just diet-adherent in EoE. Where is the dietitian? Authors' reply.
    Aliment Pharmacol Ther. 2023;57:445.
    PubMed    
    
    
    January 2023
79. MAALOUF E, Grover M
    Editorial: repurposed linaclotide and the quest for abdominal pain management in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2023;57:261-262.
    PubMed    
    
    
    December 2022
80. GOODOORY VC, Guthrie EA, Ng CE, Black CJ, et al
    Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Dec 21. doi: 10.1111/apt.17356.
    PubMed     Abstract available
    
    
    
81. FITZPATRICK JA, Halmos EP
    Editorial: gluten-free but not pain-free in IBS.
    Aliment Pharmacol Ther. 2022;56.
    PubMed    
    
    
    
82. ALGERA JP, Magnusson MK, Ohman L, Storsrud S, et al
    Editorial: gluten-free but not pain-free in IBS-authors' reply.
    Aliment Pharmacol Ther. 2022;56.
    PubMed    
    
    
    November 2022
83. QUIGLEY EMM, Markinson L, Stevenson A, Treasure FP, et al
    Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Nov 11. doi: 10.1111/apt.17310.
    PubMed     Abstract available
    
    
    
84. LEMBO A, Kuo B, Boinpally R, Li E, et al
    Randomised clinical trial: effects of MD-7246 on irritable bowel syndrome with diarrhoea.
    Aliment Pharmacol Ther. 2022 Nov 2. doi: 10.1111/apt.17274.
    PubMed     Abstract available
    
    
    
85. QUIGLEY EMM
    Editorial: 5-aminosalicylic acid fails to impact on irritable bowel syndrome-wrong population, intervention, target or hypothesis?
    Aliment Pharmacol Ther. 2022;56:1497-1498.
    PubMed    
    
    
    October 2022
86. GU Y, Xiang Y
    Letter: efficacy of peppermint oil in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022;56:1215-1216.
    PubMed    
    
    
    
87. INGROSSO MR, Ianiro G, Nee J, Lembo AJ, et al
    Letter: efficacy of peppermint oil in irritable bowel syndrome-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1217-1218.
    PubMed    
    
    
    
88. SHIN A
    Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:1300-1301.
    PubMed    
    
    
    
89. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
    Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1302-1303.
    PubMed    
    
    
    September 2022
90. ALGERA JP, Magnusson MK, Ohman L, Storsrud S, et al
    Randomised controlled trial: effects of gluten-free diet on symptoms and the gut microenvironment in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Sep 29. doi: 10.1111/apt.17239.
    PubMed     Abstract available
    
    
    
91. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:894-895.
    PubMed    
    
    
    
92. SHAH ED, Wechsler EV
    Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022;56:892-893.
    PubMed    
    
    
    August 2022
93. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
    Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up.
    Aliment Pharmacol Ther. 2022 Aug 22. doi: 10.1111/apt.17193.
    PubMed     Abstract available
    
    
    
94. INGROSSO MR, Ianiro G, Nee J, Lembo AJ, et al
    Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022 Aug 9. doi: 10.1111/apt.17179.
    PubMed     Abstract available
    
    
    
95. CASTRO TEJERA V, Ohman L, Aabakken L, Fellstrom B, et al
    Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-Effects on gastrointestinal symptoms and rectal biomarkers of immune activity.
    Aliment Pharmacol Ther. 2022 Aug 8. doi: 10.1111/apt.17182.
    PubMed     Abstract available
    
    
    July 2022
96. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
    Impact of Rome IV Irritable Bowel Syndrome on Work and Activities of Daily Living.
    Aliment Pharmacol Ther. 2022 Jul 6. doi: 10.1111/apt.17132.
    PubMed     Abstract available
    
    
    
97. LOVDAHL J, Tornblom H, Ringstrom G, Palsson OS, et al
    Editorial: group-based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome-authors' reply.
    Aliment Pharmacol Ther. 2022;56:160-161.
    PubMed    
    
    
    
98. MIKOCKA-WALUS A, Lores T
    Editorial: group-based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome.
    Aliment Pharmacol Ther. 2022;56:158-159.
    PubMed    
    
    
    
99. BIESIEKIERSKI JR, Wu J, Van Oudenhove L
    Letter: gut-brain axis dysfunction underlies symptom generation in irritable bowel syndrome-a plea for rational interpretation of irrational doses of FODMAPs. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:368-369.
    PubMed    
    
    
    
100. HALMOS EP, Gibson PR
     Letter: gut-brain axis dysfunction underlies symptom generation in irritable bowel syndrome-a plea for rational interpretation of irrational doses of FODMAPs.
     Aliment Pharmacol Ther. 2022;56:366-367.
     PubMed    
     
     
     
101. BIESIEKIERSKI JR, Manning LP, Murray HB, Vlaeyen JWS, et al
     Review article: Exclude or expose? The paradox of conceptually opposite treatments for irritable bowel syndrome.
     Aliment Pharmacol Ther. 2022 Jul 1. doi: 10.1111/apt.17111.
     PubMed     Abstract available
     
     
     June 2022
102. COFFIN PB, Duboc H
     Diagnostic and therapeutic approach to persistent abdominal pain beyond irritable bowel syndrome.
     Aliment Pharmacol Ther. 2022 Jun 2. doi: 10.1111/apt.17064.
     PubMed     Abstract available
     
     
     
103. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
     Editorial: estimating the costs of care in irritable bowel syndrome-a necessary step to enhance value-based care for a high-prevalence, low-cost condition. Authors' reply.
     Aliment Pharmacol Ther. 2022;55:1590-1591.
     PubMed    
     
     
     
104. BERINSTEIN JA, Fendrick AM
     Editorial: estimating the costs of care in irritable bowel syndrome-a necessary step to enhance value-based care for a high-prevalence, low-cost condition.
     Aliment Pharmacol Ther. 2022;55:1588-1589.
     PubMed    
     
     
     May 2022
105. LOVDAHL J, Tornblom H, Ringstrom G, Palsson OS, et al
     Randomised clinical trial: individual versus group hypnotherapy for irritable bowel syndrome.
     Aliment Pharmacol Ther. 2022 May 3. doi: 10.1111/apt.16934.
     PubMed     Abstract available
     
     
     
106. QUIGLEY EMM
     Editorial: risky business. What do sufferers' perceptions of risk from interventions for irritable bowel syndrome really mean?
     Aliment Pharmacol Ther. 2022;55:1218-1219.
     PubMed    
     
     
     
107. GOODOORY VC, Ng CE, Black CJ, Ford AC, et al
     Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom.
     Aliment Pharmacol Ther. 2022 May 1. doi: 10.1111/apt.16939.
     PubMed     Abstract available
     
     
     April 2022
108. FOX M
     Editorial: meal-induced symptoms in irritable bowel syndrome-"all in the mind"?
     Aliment Pharmacol Ther. 2022;55:880-881.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Irritable Bowel Syndrome is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum